BAXJECT III reconstitution demo video (length: 5:58)
Infusion information for ADYNOVATE
Patients should be trained on how to self-infuse by their healthcare provider or hemophilia treatment center.
ADYNOVATE prophylaxis indicated dose1
Children (< 12 years): 55 IU/kg twice weekly, with a maximum of 70 IU/kg
Adolescents and adults (12 years and older): 40-50 IU/kg twice weekly
Adjust the dose based on the patient's clinical response.
SELECTED IMPORTANT RISK INFORMATION
WARNINGS & PRECAUTIONS
Hypersensitivity Reactions: Hypersensitivity reactions are possible with ADYNOVATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with other recombinant antihemophilic factor VIII products, including the parent molecule, ADVATE. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.
See Detailed Important Risk Information below.
Having trouble with the BAXJECT III Reconstitution system?
Learn how to recover ADYNOVATE if the initial reconstitution procedure fails in the video below.
BAXJECT III reconstitution troubleshooting video (length: 6:34)
How to store and handle ADYNOVATE1
Store ADYNOVATE in powder form at 2° to 8°C (36° to 46°F)
Do not freeze
ADYNOVATE may be stored at room temperature not to exceed 30°C (86°F) for a period of up to 3 months not to exceed the expiration date
After storage at room temperature, do not return the product to the refrigerator
Do not use beyond expiration date printed on the carton or vial
Store vials in their original box and protect from extreme light exposure
After reconstitution, do not refrigerate the solution. Use the reconstituted solution immediately or within 3 hours after reconstitution. Discard any remaining solution
Learn how you and your patients can get started using the myPKFiT app